Rationale: Considerable evidence shows atherosclerosis to be a chronic inflammatory disease in which immunity to self-antigens contributes to disease progression. We recently identified the collagen type V [col(V)] ␣1(V) chain as a key autoantigen driving the Th17-dependent cellular immunity underlying another chronic inflammatory disease, obliterative bronchiolitis. Because specific induction of ␣1(V) chains has previously been reported in human atheromas, we postulated involvement of col(V) autoimmunity in atherosclerosis.
A therosclerosis is the common pathological process underlying coronary arterial disease (CAD), carotid stenosis, and peripheral arterial disease: the major causes of death and disability in Western societies. 1 Traditional therapy for atherosclerosis has consisted of risk factor modification, including treatment of hypercholesterolemia, hyperglycemia, and hypertension. It was once thought that treatment of these risk factors might eradicate cardiovascular disease by the end of the 20th century. However, because cardiovascular disease remains the leading cause of death in the Western world, a clear role for new approaches in preventing and treating atherosclerosis is evident. 2, 3 Atherosclerosis is a chronic inflammatory process regulated by a complex interplay of innate and adaptive immune responses. The concept that atherosclerosis is, at least in part, an autoimmune disease has gained considerable support, 1,4 -6 and both oxidized low-density lipoproteins (oxLDL) 2,7-9 and heat shock proteins (HSPs) 10, 11 have been identified as autoantigens involved in the disease process. The type of immune response associated with atherosclerosis includes Th1 cells and is characterized by increased production of interferon (IFN)-␥ by plaque infiltrating and peripheral blood T cells. 8 -10,12 However, the relatively recent discovery of Th17 cells, characterized by interleukin (IL)-17 and IL-22 production, and promotion of several inflammatory autoimmune diseases [13] [14] [15] necessitates considering potential roles for these cells in the autoimmunity of atherosclerosis. Consistent with this possibility, recent studies have found infiltration of both IL-17-and IFN-␥-producing T cells within vascular plaques. 16 Additionally, elevated IL-17 cytokine levels have been associated with adverse outcomes in unstable angina and acute myocardial infarction. 17, 18 Collagens are critical components of the extracellular matrix of atherosclerotic plaques, where they can constitute up to 60% of total plaque protein 19 and stimulate cellular responses central to plaque development. 20 Recently, we demonstrated that IL-17-dependent cellular autoimmunity against the ␣1(V) chain of collagen type V [col(V)] underlies bronchiolitis obliterans syndrome (BOS), the chronic inflammatory/fibroobliterative process leading to occlusion of small airways and eventual rejection of the majority of human lung transplants. 21 Pretransplant col(V)-specific autoimmunity was also identified as a significant risk factor for primary graft dysfunction, the leading cause of early morbidity and mortality after lung transplantation. 22, 23 Identification of the col(V) ␣1(V) chain as a critical autoantigen in these conditions, together with growing recognition of the autoimmune component underlying atherosclerosis, made it of interest that the ␣1(V) chain is specifically upregulated in human atherosclerotic plaques. 24 Although col(V) usually exists as ␣1(V) 2 ␣2(V) heterotrimers sequestered in the interiors of fibrils of the highly abundant collagen type I [col(I)], 25 excess ␣1(V) chains can form aberrant ␣1(V) 3 homotrimers 26 that are excluded from col(I) fibrils. 27 This suggested a model in which homotrimers comprising the excess ␣1(V) chains of atherosclerotic plaques could present normally cryptic epitopes that, in the inflammatory microenvironment of plaques, initiate autoimmunity. Here, we tested the hypothesis that cellular and/or humoral col(V) autoimmunity is a component of the chronic inflammatory response characterizing atherosclerosis. This hypothesis was tested both with peripheral blood mononuclear cells (PBMCs) from patients with known CAD, necessitating coronary artery bypass grafting (CABG), and in the apolipoprotein E knockout (ApoE Ϫ/Ϫ ) mouse model of atherosclerosis.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Human Subjects
Immunologic monitoring was performed on blood samples from patients with end stage CAD awaiting CABG. Subject consent was obtained using human subjects committee-approved, written, informed consent procedures at the University of Wisconsin Hospital and Clinics. Blood was collected and processed as described previously. 28 PBMCs from healthy volunteers served as controls (Online Table I ).
Mice
ApoE Ϫ/Ϫ mice (strain B6.129P2-Apoe tmi/Unc /J) were obtained from The Jackson Laboratory, and C57BL/6 control and DTH recipient mice from Harlan Sprague-Dawley Inc. Some mice at 8 weeks of age were shifted from regular chow (8604, Harlan Teklad) to a high-fat diet (TD.88137, Harlan Teklad), whereas some remained on regular chow. At 13 weeks, all mice were immunized subcutaneously in the inguinal region with 1.5 limits of flocculation (lf) tetanus toxoid and diphtheria (TT/DT) pediatrics vaccine (Sanofi-Aventis Pasteur). After 15 weeks, spleens, serum, hearts and aortas were collected and processed. CB17.SCID mice were purchased (Harlan Sprague-Dawley Inc) or bred locally (Gnotobiotics, University of Wisconsin, Madison). For Col(V) sensitization, mice were IV injected every 2 weeks with 50 g native bovine col(V) (a generous gift from ImmuneWorks Inc, Indianapolis, Ind) for a total of 8 injections while on regular chow. Experiments were performed in accordance with the NIH and US Department of Agriculture guidelines, after approval by the University of Wisconsin Institutional Animal Care and Use Committee.
Transvivo Delayed-Type Hypersensitivity Assay
Transvivo delayed-type hypersensitivity (TV-DTH) was performed by cotransfer of human PBMCs and antigens into the footpads of SCID mice as previously described, 29 or by injection of 8ϫ10 6 to 10ϫ10 6 mouse splenocytes into footpads of naïve B6 recipients as previously described. 30 Inactivated 5 g of Epstein Barr virus (Viral Antigens Inc) and 0.25 lf TT/DT (Sanofi-Aventis Pasteur) were used as positive control recall antigens for human and mouse cells, respectively. Bovine col(V), human col(V), and separated bovine ␣1(V) and ␣2(V) chains were all obtained from D. Brand (University of Tennessee, Memphis) and were prepared from placenta, essentially as described elsewhere. 31 Col(V) used in all panels of Figure 1 was human, with the exception of the native col(V) and separate ␣1(V) and ␣2(V) chains used in Figure 1B , which were all bovine. Col(V) used in all mouse studies was bovine. Human col(I) (BD Pharmingen), bovine col(II) (Southern Biotech), and human col(IV) (Sigma) were purchased. Collagens were tested at 5 g/injection (human) and 20 g/injection (mouse). Cytokines were neutralized by coinjection of 10 g of antibodies against human IFN-␥, IL-17, tumor necrosis factor (TNF)-␣, IL-1␤, IL-2, IL-4 (all from eBiosciences), or IL-22 (R&D Systems) or antibodies directed against mouse IFN-␥, IL-17, transforming growth factor (TGF)-␤ (all 3 from BD Pharmingen), TNF-␣, IL-1␤ (both eBiosciences), or IL-10 (R&D Systems). In some TV-DTH assays, human PBMCs were incubated with CD4, CD14, or CD8 microbeads (Miltenyi) and were depleted using autoMACS (Miltenyi). Fab fragments of anti-HLA-DR (monoclonal antibody L243) and anti-HLA class I (monoclonal antibody W6/32) were generated using a Fab micropreparation kit (Pierce) and used at 1 g/injection for neutralization experiments.
Flow Cytometry Detection of Serum Anti-col(V) Antibodies
Serum anti-col(V) antibodies were detected using streptavidincoated beads (Polyscience) bound to biotinylated bovine col(V) 
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Histological Analysis
Mouse aortic roots and arches were frozen in OCT (Tissue-Tek) or embedded in paraffin and sectioned at a thickness of 5 m over 50-m intervals for both standard hematoxylin/eosin (H&E) prepa- Col(V) Serum Antibody (MFI) rations and immunohistochemistry. Atherosclerotic plaque burden in the aortic root, composition of atherosclerotic plaques, and immunohistochemical staining were performed as described in the expanded Methods section (see the Online Data Supplement).
Statistical Analysis
Data were analyzed using GraphPad Prism 5 software (GraphPad Software, La Jolla, Calif). The nonparametric Mann-Whitney test was used to analyze all TV-DTH and antibody data. Unpaired t tests were used for all other analyses.
Results
Th17 and Th1/17 Cellular Immunity to Col(V) in Human CAD
To examine the possibility of anti-col(V) cellular autoimmunity as a component of human atherosclerosis, we tested for cellular anti-col(V) immunity in the PBMCs of patients with end-stage CAD requiring CABG. Col(V)-specific cell-mediated immunity was assessed using the transvivo delayed-type hypersensitivity (TV-DTH) assay. Figure 1A shows responses to recall antigen Epstein Barr virus, col(V), and collagen types II and I [col(II) and col(I), respectively] by PBMCs of end-stage CAD patients and of healthy normal subjects. Both groups of subjects had similar positive responses to the recall antigen and negative responses to col(II), an irrelevant collagen not found in the cardiovascular system, as well as to col(I), a collagen present in large quantities in atherosclerotic lesions. 32 However, the CAD patients had a significantly higher cellular immune response to col(V) (PϽ0.0001 versus controls) ( Figure 1A ). To determine whether this cell-mediated immune response was directed against one or both col(V) chains, separate ␣1(V) and ␣2(V) chains were tested via the TV-DTH assay. As shown in Figure  1B , the cellular reactivity of the CAD patients mapped to the ␣1(V) chain, with little to no response directed against the ␣2(V) chain. TV-DTH responses from PBMCs of control patients remained low against intact col(V) and the separate col(V) chains ( Figure 1B ).
To determine whether CD4 ϩ or CD8 ϩ T cells, as well as monocytes, mediate the col(V)-specific TV-DTH response, PBMCs from CAD patients (nϭ4) were depleted of CD4 ϩ or CD8 ϩ T cells or CD14ϩ monocytes before coinjection with col(V). Depletion of CD4 ϩ T cells abolished the col(V) swelling response, whereas CD8 ϩ T-cell depletion had no significant effect, indicating the importance of CD4 ϩ T cells in the response ( Figure 1C ). This col(V) swelling response was also inhibited in the presence of neutralizing HLA-DR Fab fragments but was not inhibited in the presence of anti-HLA class I Fab fragments, thus further supporting a role for CD4 ϩ T cells in this col(V) autoimmune response (Online Figure I) . Depletion of CD14 ϩ monocytes also abolished the col(V) swelling response, indicating that these cells are critical APCs in the col(V) response ( Figure 1C ). When PBMCs were coinjected with cytokine-neutralizing antibodies, the strong swelling response to col(V) was not affected by isotype control IgG, anti-human IL-2, or antihuman IL-4. However, the col(V) swelling response was significantly blocked by addition of anti-human IFN-␥, IL-17, IL-22, IL-1␤, and TNF-␣, with dependence on IFN-␥ being relatively variable ( Figure 1D ). When plasma samples from CAD patients and healthy controls were analyzed for the presence of anti-col(V) antibody, significant differences were not observed (Online Figure II ).
Cellular and Humoral Immunity to Col(V) in a Mouse Model of Atherosclerosis
To further explore the extent to which col(V) autoimmunity accompanies and drives atherosclerosis, we assayed for possible col(V) autoimmunity in the apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mouse model of atherosclerosis. 33 As in human atherosclerosis, early and advanced lesions in ApoE Ϫ/Ϫ mice are infiltrated by macrophages and CD4 ϩ T cells, which contribute to plaque pathogenesis, 34, 35 reflecting an immune component apparently conserved between the 2 species. ApoE Ϫ/Ϫ mice and control wild type B6 mice were fed a high fat (Western) diet for 15 weeks and all mice were immunized with TT/DT before experimentation. Splenocytes obtained from ApoE Ϫ/Ϫ mice displayed a TV-DTH col(V) response significantly higher than that of B6 controls (PϭϽ0.0001) ( Figure 2A ) and similar in magnitude to the positive control TT/DT-specific response. The response was collagen type-specific, in that DTH responses to col(I), col(II), and to the major basement membrane collagen col(IV) (Figure 2A ) were all significantly lower in comparison with the ApoE Ϫ/Ϫ col(V) response [PϽ0.005 for col(I), col(II), and col(IV)]. When splenocytes from col(V) "highresponder" ApoE Ϫ/Ϫ mice were coinjected with cytokinespecific antibodies, TV-DTH responses to col(V) were blocked by neutralization of murine IFN-␥, IL-17, and IL-1␤ ( Figure 2B ), consistent with dependence on both the Th17 and Th1 pathways, as in most human CAD patients tested ( Figure 1D ). However, unlike the human CAD patients, TV-DTH to col(V) was blocked by TNF-␣ neutralizing antibodies in only 2 of 7 ApoE Ϫ/Ϫ mice tested ( Figure 2B ). Analysis of serum samples for col(V)-specific antibodies revealed that ApoE Ϫ/Ϫ mice fed a Western diet had significantly higher levels of anti-col(V) antibodies compared to similarly fed B6 controls (Pϭ0.004, Figure 2C ), indicating involvement of B cells as well as T cells in col(V) autoimmunity in this model.
Col(V) Is Expressed in Atherosclerotic Lesions of ApoE ؊/؊ Mice on a High-Fat Diet
Aortic root and arch sections collected from ApoE Ϫ/Ϫ and control B6 mice fed a Western diet for 15 weeks were analyzed for the presence of atherosclerotic lesions and col(V) content. Representative H&E staining of the aortic sinus displayed the prototypical lesion development normally seen in ApoE Ϫ/Ϫ mice fed a high-fat diet ( Figure  3A) , with an absence of lesion development in B6 controls ( Figure 3B ). As expected, ApoE Ϫ/Ϫ mice had a significantly higher total lesion area ( Figure 3G ) and percentage of vessel occlusion attributable to plaque burden ( Figure  3H ) than did B6 controls, and macrophages were distributed throughout plaques ( Figure 3E ) as were lipids ( Figure  3F) . Importantly, analysis of advanced lesions from ApoE Ϫ/Ϫ aortae showed col(V) to be strongly expressed in intimal and medial layer regions of the lesion (Figure 3C ), consistent with a mechanism whereby local intralesional col(V) might contribute to generating the types of anticol(V) immune responses reported here. In contrast, B6 control aorta lacked detectable col(V) expression in intimal and medial layers ( Figure 3D ). Some col(V) expression was detected in B6 aortae, exclusively in vessel adventitia, with broader and more intense col(V) staining detected in the adventitia of ApoE Ϫ/Ϫ aortae ( Figure 3C and 3D). It has been suggested previously (Burlingham et al, 21 Ooshima, 24 Sumpter and Wilkes 38 ) that increased expression of col(V) in an inflammatory setting is accompanied by generation of abnormal col(V) forms, likely to be involved in triggering anti-col(V) responses. Generation of such forms may thus accompany the increased col(V) expression in ApoE Ϫ/Ϫ atheromas ( Figure 3C ), thereby contributing to induction of anti-col(V) responses.
ApoE ؊/؊ Mice Fed Regular Chow Have an IL-10-Regulated Anti-col(V) Autoimmune Response
To determine the degree to which col(V) autoimmunity in ApoE Ϫ/Ϫ mice was diet-dependent, and thus limited to mice with relatively advanced atherosclerosis on a high-fat diet, we assayed for a cellular immune response to col(V) in ApoE Ϫ/Ϫ mice maintained on regular chow. Splenocytes from ApoE Ϫ/Ϫ mice fed regular chow had a significantly lower response to col(V) compared to ApoE Ϫ/Ϫ mice fed a Western diet, with both groups displaying a low response to col(I) ( Figure 4A ). To determine whether a low col(V) response in ApoE Ϫ/Ϫ mice on regular chow was attributable to absence of col(V)-specific T effector (T E ) cells, or to regulation of an incipient response to this autoantigen, splenocytes from ApoE Ϫ/Ϫ mice fed regular chow were coinjected in the TV-DTH assay with col(V) or col(I), with or without neutralizing antibodies to TGF-␤ or IL-10. Whereas TGF-␤ neutralization only slightly increased the swelling response, IL-10 neutralization significantly uncovered a specific anticol(V) response, similar in strength to the positive control swelling response to TT/DT ( Figure 4B ). B6 age-matched controls maintained on regular chow displayed no DTH swelling response to col(V) either with or without addition of IL-10 or TGF-␤ neutralizing antibody (data not shown). These data indicate that splenocytes from ApoE Ϫ/Ϫ mice maintained on regular chow contain col(V)-specific T E cells; however, these cells are being controlled by IL-10 -producing cells.
Sensitization to Col(V) Breaks Tolerance and Results in Exacerbated Disease
To determine a possible causal relationship between col(V) autoimmunity and atherosclerosis, we sought to break tolerance via multiple exposures to col(V). ApoE Ϫ/Ϫ mice main-tained on regular chow were treated biweekly with 8ϫ50 g intravenous (IV) doses of col(V), a route that we have found to be immunogenic in the ApoE Ϫ/Ϫ mice. After 15 weeks, splenocytes, serum, and aortic roots were collected and analyzed for col(V) reactivity and disease pathology. Splenocytes showed an increased TV-DTH response to col(V) in the absence of IL-10 -mediated inhibition (Online Figure III) , consistent with intensified anti-col(V) cellular immunity. Serum analysis confirmed that col(V)-treated ApoE Ϫ/Ϫ mice were sensitized, as indicated by significantly higher titers of anti-col(V) antibodies compared to untreated ApoE Ϫ/Ϫ controls (Pϭ0.0007; Figure 5C ), reminiscent of the elevated levels of anti-col(V) antibodies seen in ApoE Ϫ/Ϫ mice on a high-fat diet ( Figure 2C ). When aortic root sections were stained for C3d deposition, plaque areas of the ApoE Ϫ/Ϫ mice sensitized to col(V) had much brighter staining compared to untreated ApoE Ϫ/Ϫ controls ( Figure 5A , bottom images), consistent with increased IgG deposition from a heightened humoral response. Importantly, aortic roots of col(V)-sensitized ApoE Ϫ/Ϫ mice showed markedly exacerbated atherosclerotic burden compared with untreated ApoE Ϫ/Ϫ mice ( Figure 5A and 5B) . Thus, in support of a causal role for col(V) autoimmunity in 
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the pathogenesis of atherosclerosis, sensitization to col(V) was sufficient to increase atherosclerotic burden in ApoE Ϫ/Ϫ mice on normal chow. Additionally, although plaques of both sensitized animals and controls had macrophages and lipids distributed throughout ( Figure 5A ), immunostaining with antibodies to CD3 revealed that, unlike untreated ApoE Ϫ/Ϫ controls, col(V)-sensitized ApoE Ϫ/Ϫ mice had large numbers of T cells infiltrating the root area ( Figure 6A ). Col(V)sensitized ApoE Ϫ/Ϫ mice also had significantly higher numbers of infiltrating T cells within the adventitia underlying the plaque, as well as in the plaques themselves, compared to untreated ApoE Ϫ/Ϫ controls, even when normalizing for the lesser plaque area of the latter ( Figure 6B ). In fact, plaques of col(V)-sensitized ApoE Ϫ/Ϫ mice seemed to have cellularity that was somewhat high for murine atherosclerotic lesions. We believe this to reflect the cellular nature of the anti-col(V) immune response, which is accentuated in lesions of col(V)sensitized ApoE Ϫ/Ϫ mice. Costaining the aortic root sections with anti-CD68 (Figure 7 , green, left) or anti-CD3 (Figure 7 , green, right) along with anti-IL-17 (red) and DAPI (blue) revealed that plaque-and adventitia-infiltrating macrophages and T cells in the col(V)-sensitized ApoE Ϫ/Ϫ mice were expressing IL-17 (Figure 7 , yellow color), whereas T cells in untreated ApoE Ϫ/Ϫ control aortic root sections remained negative for IL-17 production (data not shown). We could also detect IL-17-expressing cells (Figure 7 , red color) that were neither macrophages nor CD3 ϩ T cells throughout the adventitia and plaque area; expression that was markedly more prominent in col(V)-sensitized ApoE Ϫ/Ϫ mice than in untreated ApoE Ϫ/Ϫ controls (data not shown).
Discussion
Although high plasma LDL cholesterol and other hemodynamic factors are clearly involved in atherogenesis, atherosclerosis is a chronic inflammatory disease with an important immune component occurring at each stage of the disease. 1, 2, 5, 36, 37 It has become apparent that the proinflammatory process that affects plaque growth and destabilization, and which also perpetuates and amplifies the inflammatory state, involves autoimmune responses that develop in the lesion against local self-antigens. To date, the self-antigens have comprised HSP 60/65 10,11 and oxLDL. 2,7-9 Here we demonstrate col(V) to be an autoantigen characteristic of atherosclerosis in humans and mice. Previous studies demonstrated anti-col(V) autoimmunity to play a causal role in lung transplant rejection in rat and to be a critical component of BOS, the chronic inflammatory/ fibroobliterative process causal in rejection of most human lung transplants. 21, 38 Col(V) is a minor fibrillar collagen, broadly distributed in tissues as ␣1(V) 2 ␣2(V) heterotrimers buried in the interior of fibrils of the much more abundant col(I). 25 Because of this sequestration, col(V) has the potential to contain epitopes that are normally immunologically masked. 25 The ease of immunohistochemical detection of normally masked col(V) epitopes in rejected lung transplants 21, 38 and the finding that anti-col(V) immunity in BOS is directed exclusively against ␣1(V) chains 21 suggested a model in which aberrant ␣1(V) 3 homotrimers, excluded from the interior of col(I) fibrils, 27 might be involved in neoepitope formation and establishment of anti-col(V) immunity. In the context of this model, it was of great interest that ␣1(V) chains, capable of forming homotrimers, are specifically upregulated in human atheromas. 24 Taken together, the above observations prompted the present study into the possibility that col(V) may serve as an autoantigen in the immune responses that underlie significant pathogenesis in atherosclerosis. The finding of ␣1(V)-specific immune responses in CAD patients supports a possible role for ␣1(V) 3 homotrim- ers in neoepitope formation, although it is also possible that epitopes on sequestered ␣1(V) 2 ␣2(V) heterotrimers are exposed via fragmentation of the extracellular matrix by matrix metalloproteinases, highly active in both BOS 38 and atheromas, 9 and that ␣1(V), but not ␣2(V), epitopes induce autoimmunity. We also have not formally excluded the possibility that some col(V) neoepitopes may be created via oxidative modification by reactive oxygen species, although all anticol(V) responses described in the present report were demonstrated using nonoxidized col(V).
Here, we demonstrate that CAD patients have cellular autoimmune responses to col(V) in the absence of responses against the much more abundant fibrillar collagens, col(I) and col(II), or against ␣2(V) chains. Similarly, atherosclerotic ApoE Ϫ/Ϫ mice on a high-fat diet had highly significant and specific cellular and humoral immune responses to col(V), whereas B6 controls lacked such responses. As in human CAD, ApoE Ϫ/Ϫ anti-col(V) responses were highly specific, with no significant responses detected against the major collagen types I, II, and IV. Moreover, advanced lesions in ApoE Ϫ/Ϫ mice on a high-fat diet showed strong, readily detectable col(V) staining, demonstrating the autoantigen to be present in the mouse lesions, as previously shown for human plaques. 24 Thus, T-cell and monocyte-dependent anticol(V)-specific cellular autoimmunity is a feature not only of human CAD, but also of atherosclerotic-prone mice, suggesting col(V) autoimmunity to be a consistent feature of atherosclerosis. Ooshima 24 has suggested that the increased ␣1(V) chains of human atheromas are likely produced by intralesional smooth muscle cells. As smooth muscle cells also appear in the atheromas of ApoE Ϫ/Ϫ mice, 39 such cells are reasonable candidates as the source of col(V) that elicits autoimmune responses in this system as well. Humoral autoimmunity may be more prevalent in emerging than in late-stage atherosclerosis, possibly accounting for the discrepancy between human (assayed at end-stage CAD) and mouse (assayed at relatively early stages of atherosclerosis) anti-col(V) antibody results.
Our previous analysis of patients awaiting lung transplantation for end-stage pulmonary disease resulted in the surprising finding that the majority of patients with idiopathic pulmonary fibrosis (IPF) were strongly positive for Th17dependent col(V)-specific autoimmunity. This finding was unique to IPF, as COPD, CF, and AAD patients rarely had pretransplant cellular immunity to col(V). 23 Thus, it is of great interest that IPF patients who develop CAD have a significantly more rapid onset of CAD-related morbidity and mortality compared with the clinical course of CAD in COPD subjects. 40 These findings are thus also supportive of a role for col(V) autoimmunity in CAD.
In the present study, human CAD anti-col(V) cellular immune responses were dependent on CD4 ϩ T cells, IL-17, and IL-22, the latter a cytokine secreted by Th17 CD4 ϩ T cells and by Th22 CD4 ϩ T cells, which can play roles in chronic inflammation. 41 Also, IL-17 induces rapid production of TNF-␣ and IL-1␤ in human monocytes, a cell type known to be a critical promoter of the immunoinflammatory response in atherosclerosis, 42 and to be required for some anti-col(V) TV-DTH responses, 21, 23 and which is apparently required for anti-col(V) TV-DTH responses in CAD patients as well ( Figure 1C) . In previous studies of lung transplant patients with BOS or primary graft dysfunction, anti-col(V) cellular responses required IL-17, TNF-␣ and IL-1␤, but not IFN-␥, suggesting dependence on the Th17, but not the Th1, pathway. 21, 23 Whereas 1 of 5 CAD patients in the present study had such a cytokine pattern, some degree of dependence of the anti-col(V) cellular response on IFN-␥ was found in the other 4 patients tested. In ApoE Ϫ/Ϫ mice, anti-col(V)-specific cellular responses were also dependent on both IL-17 and IFN-␥, with more variable involvement of IL-1␤ and TNF-␣ than in human CAD. CAD has previously been shown to be associated with increased plasma levels of IL-17 17, 18 and of IL-6 and TGF-␤, 17,43 2 cytokines known to work in concert to promote Th17 cell differentiation. The finding of IL-17-producing cells in the plaques and especially in the subjacent adventitia of col(V)-sensitized mice is consistent with a potential role for Th17 cells in the progression of atherosclerosis. However, the relative importance to anti-col(V) cellular responses of IL-17 secreted in the plaque itself or secreted by cells in lymphoid organs remains to be determined. In addition, dependence of anti-col(V) cellular immunity on IFN-␥ in some CAD patients and in most ApoE Ϫ/Ϫ mice assayed suggests that col(V) autoimmunity in atherosclerosis may involve elements of the Th1 pathway as well. Involvement of elements from both Th17 (IL-17, IL-22) and Th1 (IFN-␥) cells, as well as the monocyte/macrophage product IL-1 ␤, is consistent with previous observations that both pathways are capable of inducing autoimmunity and that Th17 and Th1 pathways are not always completely separable, because some T-cell clones infiltrating human atherosclerotic lesions are capable of producing both IL-17 and IFN-␥. 16 Thus, the relative importance of elements of the Th1, Th17, and/or Th22 pathways in promoting atherosclerosis remains to be elucidated.
Although ApoE Ϫ/Ϫ mice can develop atherosclerosis even in the absence of T cells, 44, 45 it has also been clearly shown that, in the context of an intact immune system, T cells are key in regulating the pathogenesis of atherosclerotic plaques. 42, 46 Dysfunction or reduction of T R cells and resulting imbalance of the T R :T E ratio has been considered an important cause of autoimmunity 18 and may contribute to plaque inflammation and development in atherosclerosis. 47 ApoE Ϫ/Ϫ mice fed regular chow develop atherosclerotic lesions, albeit at a much slower rate than when fed a high-fat diet. In the present study, we have shown that ApoE Ϫ/Ϫ mice maintained on regular chow have IL-10mediated regulation of anti-col(V) immunity. We hypothesize that this is attributable to modulation of T E cells involved in col(V) autoimmunity by IL-10 -produced by monocytes/macrophages, and/or T R cells in early stages of plaque formation. IL-10 deficiency in ApoE Ϫ/Ϫ mice is known to promote early atherosclerotic lesion formation, characterized by increased infiltration of activated T cells and production of proinflammatory cytokines. 48 Furthermore, adoptive transfer of IL-10 -producing T R (Tr1) cells can downregulate atherosclerosis-associated pathogenic immune responses, leading to decreased plaque development and inflammation in ApoE Ϫ/Ϫ mice. 49 We speculate that the IL-10 -mediated regulation of col(V)-specific autoimmunity seen in ApoE Ϫ/Ϫ mice on regular chow contributes to slowed atherogenesis, which can be overcome by increased hypercholesterolemia attributable to high-fat diet, or by sensitization of ApoE Ϫ/Ϫ mice to col(V), in each case resulting in chronic inflammation.
An exciting aspect of the identification of proatherogenic autoantigens is the potential for specific immunomodulatory therapeutic approaches centered on such au-toantigens in attempts to prevent and treat disease. Animal studies have provided proof-of-concept results, indicating that it is possible to ameliorate atherosclerotic burden by use of vaccines and via mucosal immunization against oxLDL and HSPs, and clinical testing for other vaccines and immunomodulatory treatments for atherosclerosis are expected in the near term. 1, 2, 5, 50 Furthermore, induction of tolerance to col(V) has already been shown to prevent lung transplant acute rejection in a rat model. 51, 52 Here, we not only demonstrate an association between col(V) autoimmunity and atherosclerosis in humans and mice but also provide evidence that col(V) autoimmunity can play a causative role in the pathogenesis of atherosclerosis, because sensitization of ApoE Ϫ/Ϫ mice on normal chow to col(V) is sufficient to increase atherosclerotic burden. Thus, the observations presented herein may represent a first step toward applying immune tolerance approaches to prevent/ameliorate atherosclerosis. Because col(V) is a fibrillar collagen, another important area for future study is a possible role for col(V) autoimmunity in fibrous cap thinning and subsequent plaque rupture, leading to thromboembolic events and acute end organ ischemia, including myocardial infarction and stroke.
